



## **Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference**

GAITHERSBURG, Md. – (BUSINESS WIRE) – April 4, 2024 – Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m. ET.

A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’s website at [www.cartesiantherapeutics.com](http://www.cartesiantherapeutics.com), where an archived replay of the event will also be available for a limited time.

### **About Cartesian Therapeutics**

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit [www.cartesiantherapeutics.com](http://www.cartesiantherapeutics.com) or follow the Company on [LinkedIn](#) or [X](#), formerly known as Twitter.

### **Contact Information:**

Investor Relations:

Melissa Forst

Argot Partners

[cartesian@argotpartners.com](mailto:cartesian@argotpartners.com)

Media:

David Rosen

Argot Partners

[cartesian@argotpartners.com](mailto:cartesian@argotpartners.com)